Podcasts about drugs drugsafety

Have you taken an anti-anxiety drug long-term? Do you think you might be dependent? Do you want to know what to do next? We collected some of the most respected information on benzo tapering and provided it here in this two-part series.In today's episode, we look at possible complications, symptoms, when to take your last dose, and what it's like when you're finally benzo-free. We also answer a few questions on tapering and hear a story from San Diego, California. Welcome to Episode #42 Today, we finish our two-part series on tapering with specific information on complications, symptomology, final dosing, and what happens after you finish. We also have a unique mailbag dedicated to tapering and share a story from San Diego, California. But first, let's list the resources used in this episode, and then we'll dive deeper into the content of episode 42. Episode Index Each time listed below is in minutes and seconds. Introduction: 0:57Benzo Story: 6:12Feature: 12:47Q&A (Special Taper version of the Mailbag): 38:03Moment of Peace: 54:02 Episode Resources The following resource links are provided as a courtesy to our listeners. They do not constitute an endorsement by Benzo Free of the resource or any recommendations or advice provided therein. FEATURE: How to Taper from Benzos (Part 1)Ashton, C. Heather. Benzodiazepines: How They Work and How to Withdraw (aka The Ashton Manual). 2002. Accessed April 13, 2016. http://www.benzo.org.uk/manual.Aubrey, Allison. "Benefits Can Outweigh Risks for Pregnant Women on Anxiety Drugs or SSRIs." NPR Shots. September 18, 2017. Accessed September 18, 2017. http://www.npr.org/sections/health-shots/2017/09/18/551020800/xanax-or-zoloft-for-moms-to-be-a-new-study-assesses-safety."Direct Tapers." BenzoBuddies. Accessed March 2, 2017. http://www.benzobuddies.org/benzodiazepine-withdrawal-methods/direct-taper/.Foster, D E. Benzo Free: The World of Anti-Anxiety Drugs and the Reality of Withdrawal. Erie, Colorado: Denim Mountain Press, 2018. http://www.benzofree.org/book.Longo, Lance P. and Brian Johnson. "Addiction: Part I. Benzodiazepines — Side Effects, Abuse Risk and Alternatives." American Family Physician 61(7)(April 1, 2000):2121-28. Accessed March 6, 2017. https://www.aafp.org/afp/2000/0401/p2121.html.New South Wales Government (NSW). "Benzodiazepines." Health Fact Sheets. Last updated July 11, 2013. Accessed March 6, 2017. http://www.health.nsw.gov.au/mentalhealth/Factsheets/Pages/benzodiazepines.aspx.New York City Department of Health and Mental Hygiene (NYC DOHMH). City Health Information: Judicious Prescribing of Benzodiazepines 35(2)(2016). https://docs.wixstatic.com/ugd/990dad_167113513c9445f8bc77a77370ce649f.pdf.U.K. National Health Service (NHS). "Guidance for Prescribing and Withdrawal of Benzodiazepines & Hypnotics in General Practice." NHS Grampian. October 2006. Reviewed October 2008. https://www.benzo.org.uk/amisc/bzgrampian.pdf. U.S. Food & Drug Administration (FDA). "FDA Drug Safety Communication: FDA Updates Warnings for Oral and Injectable Fluoroquinolone Antibiotics Due to Disabling Side Effects." Drug Safety: Safety Announcement (September 26, 2016). Last updated March 8, 2018. Accessed April 10, 2018. https://www.fda.gov/Drugs/DrugSafety/ucm511530.htm. BENZO FREE LINKSWebsitePodcast Home PageFeedback FormDisclaimer Podcast Summary This podcast is dedicated to those who struggle with side effects, dependence, and withdrawal from benzos, a group of drugs from the benzodiazepine and nonbenzodiazepine classes, better known as anti-anxiety drugs, sleeping pills, sedatives, and minor tranquilizers. Their common brand names include Ambien, Ativan, Klonopin, Lunesta, Valium, and Xanax. Introduction In today's intro, I mentioned the snow we've been having and then asked everyone to just say thanks, to those in the benzo community who have been helping them out along the way. Benzo Stories

Have you taken an anti-anxiety drug long-term? Do you think you might be dependent? Do you want to know what to do next? We collected some of the most respected information on benzo tapering and provided it here in this two-part series. In today's episode, we look at possible complications, symptoms, when to take your last dose, and what it's like when you're finally benzo-free. We also answer a few questions on tapering and hear a story from San Diego, California. https://www.easinganxiety.com/post/how-to-taper-from-benzos-part-2-of-2-bfp042Video ID: BFP042 Chapters 00:57 Introduction06:12 Benzo Story12:47 Feature38:03 Q&A54:02 Moment of Peace  Resources The following resource links are provided as a courtesy to our listeners. They do not constitute an endorsement by Easing Anxiety of the resource or any recommendations or advice provided therein. FEATURE: How to Taper from BenzosAshton, C. Heather. Benzodiazepines: How They Work and How to Withdraw (aka The Ashton Manual). 2002. Accessed April 13, 2016. http://www.benzo.org.uk/manual.Aubrey, Allison. “Benefits Can Outweigh Risks for Pregnant Women on Anxiety Drugs or SSRIs.” NPR Shots. September 18, 2017. Accessed September 18, 2017. http://www.npr.org/sections/health-shots/2017/09/18/551020800/xanax-or-zoloft-for-moms-to-be-a-new-study-assesses-safety.“Direct Tapers.” BenzoBuddies. Accessed March 2, 2017. http://www.benzobuddies.org/benzodiazepine-withdrawal-methods/direct-taper/.Foster, D E. Benzo Free: The World of Anti-Anxiety Drugs and the Reality of Withdrawal. Erie, Colorado: Denim Mountain Press, 2018.  https://easinganxiety.com/book. Longo, Lance P. and Brian Johnson. “Addiction: Part I. Benzodiazepines — Side Effects, Abuse Risk and Alternatives.” American Family Physician 61(7)(April 1, 2000):2121-28. Accessed March 6, 2017. https://www.aafp.org/afp/2000/0401/p2121.html.New South Wales Government (NSW). “Benzodiazepines.” Health Fact Sheets. Last updated July 11, 2013. Accessed March 6, 2017. http://www.health.nsw.gov.au/mentalhealth/Factsheets/Pages/benzodiazepines.aspx.New York City Department of Health and Mental Hygiene (NYC DOHMH). City Health Information: Judicious Prescribing of Benzodiazepines 35(2)(2016). https://docs.wixstatic.com/ugd/990dad_167113513c9445f8bc77a77370ce649f.pdf.U.K. National Health Service (NHS). “Guidance for Prescribing and Withdrawal of Benzodiazepines & Hypnotics in General Practice.” NHS Grampian. October 2006. Reviewed October 2008. https://www.benzo.org.uk/amisc/bzgrampian.pdf.U.S. Food & Drug Administration (FDA). “FDA Drug Safety Communication: FDA Updates Warnings for Oral and Injectable Fluoroquinolone Antibiotics Due to Disabling Side Effects.” Drug Safety: Safety Announcement (September 26, 2016). Last updated March 8, 2018. Accessed April 10, 2018. https://www.fda.gov/Drugs/DrugSafety/ucm511530.htm.  The PodcastThe Benzo Free Podcast provides information, support, and community to those who struggle with the long-term effects of anxiety medications such as benzodiazepines (Xanax, Ativan, Klonopin, Valium) and Z-drugs (Ambien, Lunesta, Sonata). WEBSITE: https://www.easinganxiety.comMAILING LIST: https://www.easinganxiety.com/subscribe YOUTUBE: https://www.youtube.com/@easinganx DISCLAIMERAll content provided by Easing Anxiety is for general informational purposes only and should never be considered medical advice. Any health-related information provided is not a substitute for medical advice and should not be used to diagnose or treat health problems, or to prescribe any medical devices or other remedies. Never disregard medical advice or delay in seeking it. Please visit our website for our complete disclaimer at https://www.easinganxiety.com/disclaimer. CREDITSMusic provided / licensed by Storyblocks Audio — https://www.storyblocks.com Benzo Free Theme — Title: “Walk in the Park” — Artist: Neil Cross PRODUCTIONEasing Anxiety is produced by…Denim Mountain Presshttps://www.denimmountainpress.com ©2022 Denim Mountain Press – All Rights Reserved

Episode 282 brings you the COMPLETE guide on metformin! Every possible interaction, MoA, and question has been answered and summarized here on this episode! My goal for this is to truly summarize the full picture of metformin as too many people demonize it for reasons that literally are so insignificant, they should barely even be paid a notice. So with that in mind, get your notepads ready, this one is FULL of information! And yes, a few references for those of you that wish to read further!   REFERENCES 1. Lamanna C, Monami M, Marchionni N, Mannucci E. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2011;13(3):221–228. [PubMed] 2. Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pellegrini F, Nicolucci A. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One. 2013;8(8):e71583. [PMC free article] [PubMed] 3. Cohen RD, Woods HF. Clinical and biochemical aspects of lactic acidosis. Philadelphia: Blackwell Scientific Publications; 1976. 4. Metformin hydrochoride. Boxed warning. [October 6, 2015]. Available at: https://dailymed​.nlm​.nih.gov/dailymed/fda/fdaDrugXsl​.cfm?setid​=b8004451-7b26-425b-b5ea-cbb1b08e30e3&type=display. 5. Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014;312(24):2668–2675. [PMC free article] [PubMed] 6. Gan SC, Barr J, Arieff AI, Pearl RG. Biguanide-associated lactic acidosis. Case report and review of the literature. Arch Intern Med. 1992;152(11):2333–2336. [PubMed] 7. Goergen SK, Rumbold G, Compton G, Harris C. Systematic review of current guidelines, and their evidence base, on risk of lactic acidosis after administration of contrast medium for patients receiving metformin. Radiology. 2010;254(1):261–269. [PubMed] 8. Kajbaf F, Arnouts P, de Broe M, Lalau JD. Metformin therapy and kidney disease: a review of guidelines and proposals for metformin withdrawal around the world. Pharmacoepidemiol Drug Saf. 2013;22(10):1027–1035.[PubMed] 9. Calabrese AT, Coley KC, DaPos SV, Swanson D, Rao RH. Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy. Arch Intern Med. 2002;162(4):434–437. [PubMed] 10. Emslie-Smith AM, Boyle DI, Evans JM, Sullivan F, Morris AD. Contraindications to metformin therapy in patients with Type 2 diabetes--a population-based study of adherence to prescribing guidelines. Diabet Med. 2001;18(6):483–488. [PubMed] 11. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. [June 16, 2016]. Available at: http://www​.fda.gov/Drugs​/DrugSafety/ucm493244.htm. 12. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function—measured and estimated glomerular filtration rate. N Engl J Med. 2006;354(23):2473–2483. [PubMed] 13. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabtologia. 2015;58(3):429–442. [PubMed] 14. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis. 2012;60(5):850–886. [PubMed] 15. Flory JH, Hennessy S. Metformin use reduction in mild to moderate renal impairment: possible inappropriate curbing of use based on food and drug administration contraindications. JAMA Intern Med. 2015;175(3):458–459. [PubMed] 16. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010;(4) CD002967. [PubMed] 17. Organization for Economic Cooperation and Development. [October 20, 2015]. Available at: http://www​.oecd.org/about​/membersandpartners​/list-oecd-member-countries.htm. 18. Eurich DT, Weir DL, Majumdar SR, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail. 2013;6(3):395–402. [PubMed] 19. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461–470. [PubMed] 20. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612. [PMC free article] [PubMed] 21. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. [PMC free article] [PubMed] 22. Agency for Healthcare Research and Quality. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville, MD: Agency for Healthcare Research and Quality; [October 6, 2015]. Available at: http://www​.effectivehealthcare​.ahrq.gov/index​.cfm/search-for-guides-reviews-and-reports​/?pageaction=displayproduct&productid=318. 23. Santaguida PL, Raina P, Ismaila P. The Development of the McHarm Quality Assessment Scale for adverse events. 2012 24. Viswanathan M, Ansari M, Berkman N. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville (MD): Agency for Healthcare Research and Quality (US); Mar 8, 2012. [October 6, 2015]. Assessing the Risk of Bias of Individual Studies in Systematic Reviews of Health Care Interventions. [Internet] 2008-. Available from: http://www​.ncbi.nlm.nih​.gov/books/NBK91433/ 25. Andersson C, Olesen JB, Hansen PR, et al. Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study. Diabetologia. 2010;53(12):2546–2553. [PubMed] 26. Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care. 2005;28(10):2345–2351. [PubMed] 27. Weir DL, McAlister FA, Senthilselvan A, Minhas-Sandhu JK, Eurich DT. Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study. JACC Heart Fail. 2014;2(6):573–582. [PubMed] 28. Wang Z. Converting odds ratio to relative risk in cohort studies with partial data information. Journal of Statistical Software. 2013;55(5):1–11. 29. Dechartres A, Altman DG, Trinquart L, Boutron I, Ravaud P. Association between analytic strategy and estimates of treatment outcomes in meta-analyses. JAMA. 2014;312(6):623–630. [PubMed] 30. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188. [PubMed] 31. Knapp G, Hartung J. Improved tests for a random effects meta-regression with a single covariate. Stat Med. 2003;22(17):2693–2710. [PubMed] 32. Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401–406. [PubMed] 33. Richy FF, Sabido-Espin M, Guedes S, Corvino FA, Gottwald-Hostalek U. Incidence of lactic acidosis in patients with type 2 diabetes with and without renal impairment treated with metformin: a retrospective cohort study. Diabetes Care. 2014;37(8):2291–2295. [PubMed] 34. Eppenga WL, Lalmohamed A, Geerts AF, et al. Risk of lactic acidosis or elevated lactate concentrations in metformin users with renal impairment: a population-based cohort study. Diabetes Care. 2014;37(8):2218–2224. [PubMed] 35. Romero SP, Andrey JL, Garcia-Egido A, et al. Metformin therapy and prognosis of patients with heart failure and new-onset diabetes mellitus. A propensity-matched study in the community. Int J Cardiol. 2013;166(2):404–412. [PubMed] 36. Ito H, Ohno Y, Yamauchi T, Kawabata Y, Ikegami H. Efficacy and safety of metformin for treatment of type 2 diabetes in elderly Japanese patients. Geriatr Gerontol Int. 2011;11(1):55–62. [PubMed] 37. Sterner G, Elmståhl S, Frid A, et al. Renal function in a large cohort of metformin treated patients with type 2 diabetes mellitus. British Journal of Diabetes and Vascular Disease. 2012;12(5):227–231. 38. Zhang X, Harmsen WS, Mettler TA, et al. Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes. Hepatology. 2014;60(6):2008–2016. [PMC free article] [PubMed] 39. Becquemont L, Bauduceau B, Benattar-Zibi L, et al. Cardiovascular Drugs and Metformin Drug Dosage According to Renal Function in Non-Institutionalized Elderly Patients. Basic Clin Pharmacol Toxicol. 2015[PubMed] 40. Ekström N, Schiöler L, Svensson AM, et al. Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: A cohort study from the Swedish National Diabetes Register. BMJ Open. 2012;2:4. Article Number: e001076. [PMC free article] [PubMed] 41. Aguilar D, Chan W, Bozkurt B, Ramasubbu K, Deswal A. Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circulation: Heart Failure. 2011;4(1):53–58. [PMC free article] [PubMed] 42. Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation. 2005;111(5):583–590. [PubMed] 43. Morgan CL, Mukherjee J, Jenkins-Jones S, Holden SE, Currie CJ. Association between first-line monotherapy with sulphonylurea versus metformin and risk of all-cause mortality and cardiovascular events: a retrospective, observational study. Diabetes Obes Metab. 2014;16(10):957–962. [PubMed] 44. Roussel R, Travert F, Pasquet B, et al. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med. 2010;170(21):1892–1899. [PubMed] 45. Evans JM, Doney AS, AlZadjali MA, et al. Effect of Metformin on mortality in patients with heart failure and type 2 diabetes mellitus. Am J Cardiol. 2010;106(7):1006–1010. [PubMed] 46. Inzucchi SE, Masoudi FA, Wang Y, et al. Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project. Diabetes Care. 2005;28(7):1680–1689. [PubMed] 47. Shah DD, Fonarow GC, Horwich TB. Metformin therapy and outcomes in patients with advanced systolic heart failure and diabetes. J Card Fail. 2010;16(3):200–206. [PMC free article] [PubMed] 48. Tinetti ME, McAvay G, Trentalange M, Cohen AB, Allore HG. Association between guideline recommended drugs and death in older adults with multiple chronic conditions: population based cohort study. BMJ. 2015;351:h4984. [PMC free article] [PubMed] 49. Ampuero J, Ranchal I, Nunez D, et al. Metformin inhibits glutaminase activity and protects against hepatic encephalopathy. PloS One. 2012;7(11):e49279. [PMC free article] [PubMed] 50. Nkontchou G, Cosson E, Aout M, et al. Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. J Clin Endocrinol Metab. 2011;96(8):2601–2608. [PubMed] 51. Blonde L, Rosenstock J, Mooradian AD, Piper BA, Henry D. Glyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulphonylurea therapy. Diabetes Obes Metab. 2002;4(6):368–375. [PubMed] 52. Cryer DR, Nicholas SP, Henry DH, Mills DJ, Stadel BV. Comparative outcomes study of metformin intervention versus conventional approach the COSMIC Approach Study. Diabetes Care. 2005;28(3):539–543. [PubMed] 53. Garber AJ, Larsen J, Schneider SH, Piper BA, Henry D. Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. Diabetes Obes Metab. 2002;4(3):201–208. [PubMed] 54. Gregorio F, Ambrosi F, Manfrini S, et al. Poorly controlled elderly Type 2 diabetic patients: the effects of increasing sulphonylurea dosages or adding metformin. Diabet Med. 1999;16(12):1016–1024. [PubMed] 55. Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care. 2004;27(1):141–147. [PubMed] 56. Marre M, Howlett H, Lehert P, Allavoine T. Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance) in Type 2 diabetic patients inadequately controlled on metformin. Diabet Med. 2002;19(8):673–680. [PubMed] 57. Schweizer A, Dejager S, Bosi E. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Obes Metab. 2009;11(8):804–812.[PubMed] 58. Bannister CA, Holden SE, Jenkins-Jones S, et al. Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. Diabetes Obes Metab. 2014;16(11):1165–1173. [PubMed] 59. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabetes Care. 2008;31(11):2086–2091. [PMC free article] [PubMed] 60. Huizinga MM, Roumie CL, Greevy RA, et al. Glycemic and weight changes after persistent use of incident oral diabetes therapy: a Veterans Administration retrospective cohort study. Pharmacoepidemiol Drug Saf. 2010;19(11):1108–1112. [PubMed] 61. Leung S, Mattman A, Snyder F, Kassam R, Meneilly G, Nexo E. Metformin induces reductions in plasma cobalamin and haptocorrin bound cobalamin levels in elderly diabetic patients. Clin Biochem. 2010;43(9):759–760. [PubMed] 62. Roumie CL, Hung AM, Greevy RA, et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med. 2012;157(9):601–610. [PMC free article] [PubMed] 63. Wang CP, Lorenzo C, Espinoza SE. Frailty Attenuates the Impact of Metformin on Reducing Mortality in Older Adults with Type 2 Diabetes. J Endocrinol Diabetes Obes. 2014;2(2) [PMC free article] [PubMed] 64. Tzoulaki I, Molokhia M, Curcin V, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ. 2009;339:b4731. [PMC free article] [PubMed] 65. American Diabetes Association. Standards of Medical Care in Diabetes--2016. [June 30, 2016]. Available at: http://care​.diabetesjournals​.org/content/39/Supplement_1. 66. Bolen S, Tseng E, Hutfless S, et al. Diabetes Medications for Adults With Type 2 Diabetes: An Update.Rockville (MD): Agency for Healthcare Research and Quality (US); 2016. AHRQ Comparative Effectiveness Reviews. 67. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140–149. [PubMed] 68. Tuot DS, Lin F, Shlipak MG, et al. Potential impact of prescribing metformin according to eGFR rather than serum creatinine. Diabetes Care. 2015;38(11):2059–2067. [PMC free article] [PubMed] 69. Palmer SC, Mavridis D, Nicolucci A, et al. Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis. Jama. 2016;316(3):313–324. [PubMed] 70. MacDonald MR, Eurich DT, Majumdar SR, et al. Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database. Diabetes Care. 2010;33(6):1213–1218. [PMC free article] [PubMed] 71. U.S. Department of Veterans Affairs. Office of Research & Development. VA CSP Study No. 597: Diuretic Comparison Project. [August 29, 2016]. Available at: http://www​.research.va​.gov/programs/csp/597/ 72. Canadian Diabetes Association. Clinical Practice Guidelines: Pharmacotherapy for Type 2 Diabetes. [June 30, 2016]. Available at: http://guidelines​.diabetes​.ca/bloodglucoselowering​/pharmacologyt2-(1) 73. Gong L, Goswami S, Giacomini KM, Altman RB, Klein TE. Metformin pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2012;22(11):820–827. [PMC free article] [PubMed] 74. Weir MA, Gomes T, Mamdani M, et al. Impaired renal function modifies the risk of severe hypoglycaemia among users of insulin but not glyburide: a population-based nested case-control study. Nephrol Dial Transplant. 2011;26(6):1888–1894. [PubMed]      •••SUPPORT OUR SPONSORS•••   (COACHING) Alex - www.theprepcoach.com   (FREE OPEN FORUM w/ EXCLUSIVE VIDEOS) http://www.theprepcoachforum.com   (SUPPLEMENTS) www.projectad.me___use discount code “BFR25” to save off your order!   (RESEARCH CHEMS) www.maresearchchems.net___use discount code “alex15” to save off your order!   (SPECIALTY SUPPS) www.masupps.com___use discount code “alex20” to save off your order!   (INJECTABLE L-CARNITINE) www.synthetek.com___use discount code “alexkikel” to save off your order!   (BULK SUPPLEMENTS) www.truenutrition.com___use discount code “AXK5” to save off your order!       •••FIND THE EPISODES•••   ITUNES:https://itunes.apple.com/us/podcast/beastfitness-radios-podcast/id1065532968   LIBSYN:http://beastfitnessradio.libsyn.com   VIMEO: www.vimeo.com/theprepcoach        •••PREP COACH APPAREL•••   https://teespring.com/stores/the-prep-coach-apparel    

What did you learn from this episode? Complete our short survey to let us know! Participants will be entered into a drawing to win a $25 Amazon gift card and some Poison Control swag. The winner will be announced on our next episode! SHOW NOTES: Summary:This episode will discuss a couple of special populations that have been affected by the opioid epidemic, addressing why it is necessary to look at these groups individually, and how each requires a different approach to achieve resolution of the problem. Further Reading: • MedlinePlus: Pregnancy and Opioids: https://medlineplus.gov/pregnancyandopioids.html• The American College of Obstetricians and Gynecologists: Opioid Use Disorder and Pregnancy FAQs: https://www.acog.org/Patients/FAQs/Opioid-Use-Disorder-and-Pregnancy• Prenatal Buprenorphine Versus Methadone Exposure and Neonatal Outcomes: Systematic Review and Meta-Analysis: https://academic.oup.com/aje/article/180/7/673/150018• National Institute on Drug Abuse: Treating Opioid Use Disorder During Pregnancy: https://www.drugabuse.gov/publications/treating-opioid-use-disorder-during-pregnancy/treating-opioid-use-disorder-during-pregnancy#ref• Public Health Surveillance of Prenatal Opioid Exposure in Mothers and Infants: https://pediatrics.aappublications.org/content/143/3/e20183801#ref-3• Jansson LM, Patrick SW. Neonatal Abstinence Syndrome. Pediatr Clin North Am. 2019 Apr;66(2):353-367. doi: 10.1016/j.pcl.2018.12.006. Review. https://www.ncbi.nlm.nih.gov/pubmed/30819342• Use of Codeine and Tramadol Products in Breastfeeding Women - Questions and Answers: https://www.fda.gov/Drugs/DrugSafety/ucm118113.htm• MotherToBaby: Fact Sheets: https://mothertobaby.org/fact-sheets-parent/• Substance Use During Pregnancy: https://www.guttmacher.org/state-policy/explore/substance-use-during-pregnancy• White Paper: Opioid Use, Misuse, and Overdose in Women: https://www.womenshealth.gov/files/documents/white-paper-opioid-508.pdf • Final Report: Opioid Use, Misuse, and Overdose in Women: https://www.womenshealth.gov/files/documents/final-report-opioid-508.pdf• HHS Mental Health and Addiction Insurance Help: https://www.hhs.gov/programs/topic-sites/mental-health-parity/mental-health-and-addiction-insurance-help/index.html• Parental Substance Use and the Child Welfare System: https://www.childwelfare.gov/pubPDFs/parentalsubabuse.pdf MUSIC CREDITS:Blue Dot Sessions - Upper RegistersScott Holmes - So HappyAudiobinger - Memory Lane For more POISON!, follow us on Twitter @NationalCapital, and subscribe to our newsletter on our website, www.poison.org. Support the National Capital Poison Center today at www.poison.org/donate

This episode will give you the effects of statins and what your doctor should be telling you.  You can contact us at yopi@post.com You can also read this episode on our blog at www.yopistudio.com Feel free to check us out daily at the following and see what we are up to.  https://twitter.com/Dauricee https://www.facebook.com/yopistudio/ https://www.facebook.com/Louisiana-Entertainment-Association-671304786265477/ For further reading on this topic check out the references below. Mayo Clinic Staff. (2014, March 5). Memory loss: 7 tips to improve your memorymayoclinic.org/healthy-lifestyle/healthy-aging/in-depth/memory-loss/art-20046518 Mayo Clinic Staff. (2015, April 8). Statins: Are these cholesterol-lowering drugs right for you? Retrieved frommayoclinic.org/diseases-conditions/high-blood-cholesterol/in-depth/statins/art-20045772 Mayo Clinic Staff. (2013, April 24). Statin side effects: Weigh the benefits and risksmayoclinic.org/diseases-conditions/high-blood-cholesterol/in-depth/statin-side-effects/art-20046013 Neel, A. B. (2015, June). 10 drugs that may cause memory lossaarp.org/health/brain-health/info-05-2013/drugs-that-may-cause-memory-loss.html#quest1 New heart disease and stroke prevention guidelines released. (2013, November 12)blog.heart.org/new-heart-disease-and-stroke-prevention-guidelines-released/ Statins don’t cause memory loss, study reaffirms. (2013, December 9)health.clevelandclinic.org/2013/12/statins-dont-cause-memory-loss-study-reaffirms/ Statin medications may prevent dementia and memory loss with longer use, while not posing any short-term cognition problems. (2013, October 1)hopkinsmedicine.org/news/media/releases/statin_medications_may_prevent_dementia_and_memory_loss_with_longer_use_while_not_posing_any_short_term_cognition_problems What you should know about: Generic vs. brand-name statins. (2013, September 1)health.harvard.edu/heart-health/what-you-should-know-about-generic-vs-brand-name-statins Coping with memory loss. (2010, January 6)fda.gov/ForConsumers/ConsumerUpdates/ucm107783.htm FDA drug safety communication: Important safety label changes to cholesterol-lowering statin drugs. (2012, July 3)fda.gov/Drugs/DrugSafety/ucm293101.htm FDA expands advice on statin risks. (2014, January 31)fda.gov/ForConsumers/ConsumerUpdates/ucm293330.htm Higher dementia risk linked to more use of common drugs. (2015)sop.washington.edu/higher-dementia-risk-linked-use-common-drugs/ Jamolowicz, A., Huei-Yang, C., & Panegyres, P. (2015). Statins and memory loss: An Australian perspective. Australasian Medical Journal, 73-79 https://www.ncbi.nlm.nih.gov/pubmed/22626835ncbi.nlm.nih.gov/pmc/articles/PMC4385811/ https://www.ncbi.nlm.nih.gov/pubmed/26624886                              

5 common medications classes which cause nutritional deficiencies include acid reducers, diabetic medications, cholesterol medications diuretic blood pressure medications and birth control pills. Based on my article: https://iherb.co/2knTCQhG Sources: 1. Supplement Your Prescription Copyright 2007 by Hyla Class, MD 2. Drug Muggers by Suzy Cohen, RPh. Copyright 2011, Rodale Publishing. 3. FDA warns PPIs lower Magnesium -https://www.fda.gov/Drugs/DrugSafety/ucm245011.htm 4. Statin Use and 25-Hydroxyvitamin D Blood Level Response to Vitamin D Treatment of Older Adults. Journal American Geriatrics Society. 2017 Jun;65(6):1267-1273. DISCLAIMER: This podcast is not intended to provide a diagnosis, treatment or medical advice. Opinions by Dr. Madrid are for INFORMATIONAL purposes only. Please consult with your physician regarding your situation as each individual situation will vary.

Author: Arthur Lessen M.D. Educational Pearls: Zofran (ondansetron) is generally safe to use for the treatment of nausea and vomiting. However, it can prolong the QT interval and increase the chance for torsades.   Low doses of Zofran are not likely to be an issue. However, when multiple doses are given, especially in the setting of a preexisting LQTS, clinical concern should be raised. When giving Zofran to a patient with an increased risk for torsades, consider continuous cardiac monitoring or an alternate anti-emetic.   References:  https://www.fda.gov/Drugs/DrugSafety/ucm310190.htm  

In July 2016 the FDA released a serious new health warning for a group of antibiotics due to their "disabling side effects". In this episode Angela uncovers for us the potential dangers and irreversible side effects this popular class of antibiotics - Fluoroquinolone's. In 2010 Levaquin, an antibiotic in this category, was the best selling antibiotic in the USA. We now know that this group of drugs carries a hefty risk of damaging side effects such as: Tendon rupture, blood clots, wide spread muscle & joint pain (fibromyalgia and arthritis), retinal detachment and other vision issues, depression, neurological conditions and much more! Listen in to learn more and get educated on other options which should be considered first before ever using this class of antibiotics, so you can make informed decisions for you and your family.   Shownotes & Resources: Fluoroquinolone Antibiotics - also sold under the following brand and generic names: Cipro, ciprofloxacin, Cipro XR, Proquin XR, gemifloxacin, Factive, levofloxacin, Levaquin, moxifloxacin, Avelox, norfloxacin, Noroxin, and ofloxacin, Floxin. Make sure to keep this list of antitibiotics with you next time you go to the doctor and if they want to prescribe one of these, ask them to use a different antibiotic first. In 99% of cases there ARE other options, so don't allow yourself to be pressured into taking this class of antibiotics.   Links discussed in the show: Facebook support group for people suffering from Fluoroquinalone Side Effects - https://www.facebook.com/groups/floxies/ and https://www.facebook.com/groups/191063714251094/ FDA - Health & Safety Warning released in July 2016 https://www.fda.gov/Drugs/DrugSafety/ucm500143.htm FDA - list of generic and brand names of the fluoroquinalone group of drugs and additional side effects https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm126085.htm New York Times news article referenced in the show - this also has some additional links in the article. https://well.blogs.nytimes.com/2012/09/10/popular-antibiotics-may-carry-serious-side-effects/?_r=2 https://www.lawyersandsettlements.com/articles/warnings-fluoroquinolone-antimicrobial-drugs/interview-mark-girard-fda-fluoroquinolones-toxicity-20065.html#comment   -   Thanks for listening. If you enjoyed this episode the best compliment you can give is a referral, so please share this with your friends and remember to subscribe on iTunes or Stitcher and write us a review! This show is about you, the listener, so get involved and send us your feedback, questions and topic suggestions at busbynaturopathics.com/podcast -  email us at podcast@busbynaturopathics.com or give us a call 0416-775-530 (for int. 0011 61 416-775-530) Join us in the health journey by following us on: Facebook | Instagram | Youtube Please note: The information given in this podcast is for informational purposes only it is not intended as personal medical advise or treatment. We recommend that you seek advise from a licensed health care professional for your own personal circumstances before applying any new treatments discussed in this podcast.